Rapt Therapeutics (NASDAQ:RAPT – Get Free Report)‘s stock had its “equal weight” rating reiterated by research analysts at Barclays in a report issued on Wednesday,Benzinga reports. They currently have a $58.00 price objective on the stock. Barclays‘s target price would suggest a potential upside of 0.69% from the company’s current price. Several other research firms [...]
Barclays Reaffirms Equal Weight Rating for Rapt Therapeutics (NASDAQ:RAPT)
